-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 23, 2022, Pfizer announced positive top-line results from a Phase 3 clinical trial of etrasimod (ADP334)
UC is a chronic, often debilitating inflammatory bowel disease
Etrasimod was developed by Arena Pharmaceuticals, which was acquired by Pfizer in December
Image source: Pfizer's official website
This multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial enrolled 354 patients with UC who had previously failed or were intolerant to at least one conventional therapy/biologic/JAK therapy
References:
[1] Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients.